I couldn't figure out what these antibiotics were supposed to do to possibly have better functional outcomes. So ask your doctor who should know.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2962456-9/fulltext?rss=yes
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
,
Published Online: 19 January 2015
Summary
Background
In
adults with acute stroke, infections occur commonly and are associated
with an unfavourable functional outcome. In the Preventive Antibiotics
in Stroke Study (PASS) we aimed to establish whether or not preventive
antimicrobial therapy with a third-generation cephalosporin,
ceftriaxone, improves functional outcome in patients with acute stroke.
Methods
In
this multicentre, randomised, open-label trial with masked endpoint
assessment, patients with acute stroke were randomly assigned to
intravenous ceftriaxone at a dose of 2 g, given every 24 h intravenously
for 4 days, in addition to stroke unit care, or standard stroke unit
care without preventive antimicrobial therapy; assignments were made
within 24 h after symptom onset. The primary endpoint was functional
outcome at 3 months, defined according to the modified Rankin Scale and
analysed by intention to treat. The primary analysis was by ordinal
regression of the primary outcome. Secondary outcomes included death,
infection rates, antimicrobial use, and length of hospital stay.
Participants and caregivers were aware of treatment allocation but
assessors of outcome were masked to group assignment. This trial is
registered with
controlled-trials.com, number ISRCTN66140176.
Findings
Between
July 6, 2010, and March 23, 2014, a total of 2550 patients from 30
sites in the Netherlands, including academic and non-academic medical
centres, were randomly assigned to the two treatment groups: 1275
patients to ceftriaxone and 1275 patients to standard treatment (control
group). 12 patients (seven in the ceftriaxone group and five in the
control group) withdrew consent immediately after randomisation, leaving
2538 patients available for the intention-to-treat-analysis (1268 in
the ceftriaxone group and 1270 in the control group). 2514 (99%) of 2538
patients (1257 in each group) completed 3-month follow-up. Preventive
ceftriaxone did not affect the distribution of functional outcome scores
on the modified Rankin Scale at 3 months (adjusted common odds ratio
0·95 [95% CI 0·82–1·09], p=0·46). Preventive ceftriaxone did not result
in an increased occurrence of adverse events. Overgrowth infection with
Clostridium difficile occurred in two patients (<1%) in the ceftriaxone group and none in the control group.
Interpretation
Preventive
ceftriaxone does not improve functional outcome at 3 months in adults
with acute stroke. The results of our trial do not support the use of
preventive antibiotics in adults with acute stroke.
Funding
Netherlands Organization for Health Research and Development, Netherlands Heart Foundation, and the European Research Council.
To read this article in full you will need to make a payment
No comments:
Post a Comment